Related Experiment Videos
High-dose melphalan dosage adjustment: possibility of using a test-dose
B Tranchand1, Y D Ploin, M P Minuit
1Centre Léon Bérard, Lyon, France.
Cancer Chemotherapy and Pharmacology
|January 1, 1989
Summary
High-dose melphalan (HDM) pharmacokinetics vary greatly. This study shows a test dose accurately predicts the therapeutic dose needed for a specific drug exposure (AUC), improving treatment individualization.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Oncology
Background:
- High-dose melphalan (HDM) exhibits significant interindividual pharmacokinetic variability.
- Accurate dosing is crucial for optimizing therapeutic outcomes and minimizing toxicity.
Purpose of the Study:
- To assess the linearity and reproducibility of melphalan pharmacokinetics.
- To determine if a test dose can reliably predict the required therapeutic dose for a target area under the curve (AUC).
Main Methods:
- Two patient groups were studied: repeatability (n=8, 2-hour interval) and linearity (n=10, 24-hour interval).
- Dose ratios varied from 1-8 in the repeatability stage and 2.6-10 in the linearity stage.
- Pharmacokinetic parameters, specifically AUC, were measured and compared to predictions from a test dose.
Main Results:
- Linear pharmacokinetics of melphalan were supported by the data.
- A strong correlation was observed between measured and predicted AUC values in both stages (r = 0.929 and r = 0.943).
Conclusions:
- Melphalan pharmacokinetics demonstrate linearity and reproducibility within patients.
- A test dose regimen is a viable strategy to individualize subsequent high-dose melphalan therapy based on predicted AUC.